Inhaled corticosteroids: potency, dose equivalence and therapeutic index

Peter T Daley-Yates, Peter T Daley-Yates

Abstract

Glucocorticosteroids are a group of structurally related molecules that includes natural hormones and synthetic drugs with a wide range of anti-inflammatory potencies. For synthetic corticosteroid analogues it is commonly assumed that the therapeutic index cannot be improved by increasing their glucocorticoid receptor binding affinity. The validity of this assumption, particularly for inhaled corticosteroids, has not been fully explored. Inhaled corticosteroids exert their anti-inflammatory activity locally in the airways, and hence this can be dissociated from their potential to cause systemic adverse effects. The molecular structural features that increase glucocorticoid receptor binding affinity and selectivity drive topical anti-inflammatory activity. However, in addition, these structural modifications also result in physicochemical and pharmacokinetic changes that can enhance targeting to the airways and reduce systemic exposure. As a consequence, potency and therapeutic index can be correlated. However, this consideration is not reflected in asthma treatment guidelines that classify inhaled corticosteroid formulations as low-, mid- and high dose, and imbed a simple dose equivalence approach where potency is not considered to affect the therapeutic index. This article describes the relationship between potency and therapeutic index, and concludes that higher potency can potentially improve the therapeutic index. Therefore, both efficacy and safety should be considered when classifying inhaled corticosteroid regimens in terms of dose equivalence. The historical approach to dose equivalence in asthma treatment guidelines is not appropriate for the wider range of molecules, potencies and device/formulations now available. A more robust method is needed that incorporates pharmacological principles.

Keywords: Corticosteroid; dose equivalence; inhaled; potency; therapeutic index.

© 2015 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.

Figures

Figure 1
Figure 1
Chemical structures of synthetic glucocorticoids
Figure 2
Figure 2
Relationship between glucocorticoid receptor binding affinity (Table 1) and mid-range nominal therapeutic daily doses [53] of inhaled corticosteroids (ICS) (r2 = 0.980)
Figure 3
Figure 3
Relationship between glucocorticoid receptor binding affinity (Table 1) and estimated daily lung dose [53, 54] (Table 1) for therapeutic doses in low- (♦) (r2 = 0.825), mid- (▲) (r2 = 0.934) and high- (▪) dose ranges (r2 = 0.947) of inhaled corticosteroids (ICS). This analysis includes ICS dose regimens that are not approved for clinical use
Figure 4
Figure 4
Relationship between glucocorticoid receptor binding affinity (Table 1) and the corresponding inhaled corticosteroid glucocorticoid receptor dissociation constant (Kd, nmol l–1), which is the concentration needed to occupy 50% of glucocorticoid receptors
Figure 5
Figure 5
Relationship between glucocorticoid receptor binding affinity (Table 1) and the therapeutic index for various inhaled corticosteroid dose regimens. Therapeutic index is defined as the daily dose that produces 20% cortisol suppression divided by either the low–mid (♦) or mid–high (▲) therapeutic daily dose [23,53,54]

References

    1. Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003;43:1216–27.
    1. Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol. 1998;102:S36–51.
    1. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, Fish JE, Israel E, Lazarus SC, Lemanske RF. Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Am J Respir Crit Care Med. 1996;153(6):1739–48.
    1. Daley-Yates PT. The clinical utility of pharmacokinetics in demonstrating bioequivalence of locally acting orally inhaled drugs. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Respiratory Drug Delivery. Davis. River Grove: Healthcare International Publishing; 2010. pp. 273–83. 1.
    1. Hochhaus G, Mollmann H, Derendorf H, Gonzalez-Rothi RJ. Pharmacokinetic and pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol. 1997;37:881–92.
    1. Clark TJH. Effect of beclomethasone dipropionate delivered by aerosol in patients with asthma. Lancet. 1972;1:1361–4.
    1. Daley-Yates PT. Pharmacological aspects of glucocorticoid therapy. In: Wolthers OD, editor. Exogenous Glucocorticoids in Paediatric Asthma. Kerala: Transworld Research Network; 2007. pp. 1–18.
    1. Valotis A, Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8:54.
    1. Brindley C, Mackie AE, Falcoz C, Bye A. Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy subjects. Clin Pharmacokinet. 2000;39(Suppl. 1):8.
    1. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med. 1997;91(Suppl. A):22–8.
    1. Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, Uings IJ, Gray DW. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:660–7.
    1. Rossios C, To Y, To M, Ito M, Barnes PJ, Adcock IM, Johnson M, Ito K. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol. 2011;670:244–51.
    1. Jerre A, Sjölin P, Silberstein D, Wieslander E. Cellular uptake and fatty acid esterification of budesonide and ciclesonide in protein-rich medium. Proc Am Thoracic Society. 2006;3:A73.
    1. Boulet LP, Cowie RL, Negro RD, Brett W, Gold M, Marques A, Thorburn WS, Stepner NM, Robson R. Comparison of once- with twice-daily dosing of fluticasone propionate in mild and moderate asthma. Can Respir J. 2000;7:239–47.
    1. Woodcock A, Bleecker ER, Busse WW, Lötvall J, Snowise NG, Frith L, Jacques L, Haumann B, Bateman ED. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011;12:160.
    1. Daley-Yates PT. Relationship between pharmacokinetic and aerodynamic particle size distribution properties for inhalers containing corticosteroids. Respiratory Drug Delivery. 2014;1:163–72.
    1. Masoli M, Holt S, Weatherall M, Beasley R. Dose–response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004;23:552–8.
    1. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose–response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001;323:253–6.
    1. Molina DK, DiMaio VJ. Normal organ weights in men: part II – the brain, lungs, liver, spleen, and kidneys. Am J Forensic Med Pathol. 2012;33:368–72.
    1. Mortimer KJ, Tata LJ, Smith CJP, West J, Harrison TW, Tattersfield AE, Hubbard RB. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax. 2006;61:405–8.
    1. Daley-Yates PT, Harker AJ, Taylor S, Daniel MJ. Plasma protein binding of inhaled corticosteroids: reappraisal of its significance in systemic pharmacological activity. J Allergy Clin Immunol. 2005;115:S4.
    1. Wolthers OD, Daley-Yates PT. Exogenous Glucocorticoids in Paediatric Asthma, eds Wolthers OD. Kerala: Transworld Research Network; 2007. Inhaled glucocorticoids and hypothalamic–pituitary–adrenal axis function; pp. 19––34.
    1. Daley-Yates PT, Pierre LN. A physiologically based pharmacokinetic/pharmacodynamic model predicting cortisol suppression for inhaled corticosteroids. Am J Respir Crit Care Med. 2001;163:A518.
    1. Casale TB, Nelson HS, Stricker WE, Kenneth HR, Newman B. Suppression of hypothalamic–pituitary–adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol. 2001;87:379–85.
    1. Wilson AM, McFarlane LC, Lipworth BJ. Dose–response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med. 1997;156:1274–7.
    1. Sorkness CA, LuForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic–pituitary–adrenal axis in adult patients with asthma. Clin Ther. 1999;2(1):353–67.
    1. Möllmann H, Wagner M, Krishnaswami S, Dimova H, Tang Y, Falcoz C, Daley-Yates PT, Krieg M, Stöckmann R, Möllmann AC, Derendorf H, Hochhaus G. Single dose and steady state pharmacokinetic and pharmacodynamic evaluation of equipotent doses of inhaled fluticasone propionate and budesonide in healthy subjects. J Clin Pharmacol. 2001;41:1329–38.
    1. Daley-Yates PT, Bagen S, Tournant J, Pereira A. Beclomethasone dipropionate chlorofluorocarbon and hydrofluoroalkane metered dose inhalers: relationship between systemic exposure, dose, fine particle mass and particle size in healthy volunteers. Eur Resp J. 1999;14(30):P1358.
    1. Derom E, Van De Velde V, Marissens S, Engelstatter R, Vincken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine monophosphate in asthmatic patients. Pulm Pharmacol Ther. 2005;18:328–36.
    1. Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic–pituitary–adrenal axis in asthmatic subjects. Chest. 2005;128:70–7.
    1. Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of fluticasone propionate and mometosone furoate. Clin Ther. 2001;23:1339–54.
    1. Daley-Yates PT, Derks MGM, Weeks AT, Mehta RS, Beerahee M, Sousa A. Pharmacokinetics and pharmacodynamics of fluticasone propionate and mometasone furoate dry powder inhalers in healthy and asthmatic subjects. Am J Respir Crit Care Med. 2005;2:A354.
    1. Allen A. The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmacokinet. 2013;52:885–96.
    1. FFA103096. A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of fluticasone furoate (GW685698X) and fluticasone propionate (FP) on twenty-four hour serum cortisol in healthy subjects. Study Period: October 2004 – March 2005. Available at st accessed 8 March 2015)
    1. Brutsche MH, Brutsche IC, Munavvar M, Langley S, Masterson C, Daley-Yates PT, Brown R, Woodcock AA. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in subjects with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000;356:556–61.
    1. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2003;58(Suppl. 1):i1–94.
    1. Global Initiative for Asthma. 2014. Global strategy for asthma management and prevention. Available at (last accessed 8 March 2015)
    1. Suarez E, Fang S, Abraham J, DiSantostefano RL, Stempel DA, Frith L, Barnes NC. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review. Thorax. 2014;69(Suppl. 2):A182.
    1. Hogger P, Rohdewald P. Glucocorticoid receptors and fluticasone propionate. Rev Contemp Pharmacother. 1998;9:501––22.
    1. Daley-Yates PT, Kunka RL, Shen YY, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol. 2004;60:265–8.
    1. Falcoz C, Oliver R, McDowall J, Ventresca GP, Bye A, Daley-Yates PT. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet. 2000;39(Suppl. 1):9–15.
    1. Taylor S, Harker A. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal. 2006;41:299–303.
    1. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Bart J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S440–6.
    1. Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin Ther. 2006;28:319–31.
    1. Mager DE, Jusko WJ. Quantitative structure–pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci. 2001;91:2442–51.
    1. Agertoft L, Pedersen S. Lung deposition and systemic bioavailability of fluticasone Diskus and budesonide Turbuhaler. Am J Respir Crit Care Med. 2003;168:779–82.
    1. Mackie AE, McDowall JE, Falcoz C, Ventresca GP, Bye A. Daley-Yates PT. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy subjects. Clin Pharmacokinet. 2000;39(1):23–30.
    1. Thorsson L, Edsbacker S, Conradson TB. Lung deposition from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur Respir J. 1994;7:1839–44.
    1. Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulised budesonide in pre-school children with asthma. Arch Dis Child. 1999;80:241–7.
    1. Jeal W, Faulds D. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs. 1997;53:257–80.
    1. Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Sourgens H, Erdmann M. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol. 1995;35:302–5.
    1. Barth J, Damoiseaux M, Möllmann H, Brandis KH, Hochhaus G, Derendorf H. Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol. 1992;30:317–24.
    1. Electronic Medicines Compendium. Datapharm Communications Limited,1999. Available at (last accessed 8 March 2015)
    1. FDA approved drug products. FDA center for drug evaluation and research, office of communications, division of online communications, 2014. Available at (last accessed 8 March 2015)

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi